SLC5A2 and myotonic dystrophy type 2: Moreover, regarding SGLT2 inhibitors, their benefits in NAFLD treatment for patients with DM2 have been proven by numerous studies, which have shown that SGLT2 inhibitors enhance glycemic control, with reductions in the visceral fat amount and weight, which can improve liver steatosis [104,105,106,107,108,109].